Ozempic Lawsuit Lawyer – November 2025

Articles and advertisements for the prescription drug Ozempic are all over the web, television, print, and more. You may see remarkable weight loss stories featuring some celebrities who easily dropped a lot of weight by taking Ozempic.

However, many horror stories illustrate serious Ozempic side effects and the medical issues that can accompany this product.

At Dolman Law Group, our personal injury attorneys keep a close eye on each Ozempic lawsuit filed by patients who face the severe side effects of Ozempic use. Our mission is to protect people facing Ozempic problems and hold the manufacturer and others accountable for the harm they caused. 

If you or someone you love was prescribed Ozempic and are struggling with Ozempic side effects, contact the experienced dangerous drug lawyers at Dolman Law Group. We can explain how filing an Ozempic lawsuit could help you receive the compensation you need to move forward.

How Does Ozempic Work, and Which Conditions Does It Treat?

Ozempic is the brand name of an FDA-approved drug manufactured by Novo Nordisk originally intended to treat type-2 diabetes. The drug, also known as semaglutide, is a GLP-1 Receptor Agonist Analog-Type drug used to control high blood sugar in type 2 diabetics. 

Ozempic and other similar GLP-1 drugs are administered with an injector pen, which pumps the medication into the patient, usually once a week. Because so many diabetic patients reported losing weight while using Ozempic, the drug is now prescribed “off-label” for weight loss.

In basic terms, drugs like Ozempic mimic the effect of the incretin glucagon-like peptide-1 (GLP-1) that helps regulate the patient’s blood sugar levels. Ozempic stops the liver from producing excess sugar and stimulates the pancreas to create insulin, both of which are important concerns for people with type-2 diabetes. 

So far, Ozempic has helped many people treat their diabetes and lose weight. However, some patients also report terrible Ozempic side effects and serious health conditions that they had no idea the drug could cause.  

What Ozempic Side Effects Are Patients Reporting?  

Stomach Paralysis and Digestive Issues

In July 2023, scientists learned that when patients use Ozempic and other similar drugs like Wegovy for weight loss, they may face serious digestive problems, including stomach paralysis (gastroparesis), extensive vomiting, constipation, and other gastrointestinal concerns.

In September, the FDA finally required Ozempic’s label to warn about an increased risk of ileus, which causes an obstruction of food and liquid in the colon. 

These digestive problems have been linked to taking Ozempic and similar drugs over a long period of time at the higher dosage required for weight loss treatment. Stomach paralysis, ileus, and other digestive issues can cause serious damage and even permanently impact the patient’s quality of life.

Many people suffering from these digestive issues are involved in Ozempic stomach paralysis lawsuits throughout the nation. 

More Research Linking Ozempic to Stomach and Digestive Issues Supports the Formation of an Ozempic Lawsuit Multi-District Litigation (MDL)

At the start of October 2023, the Journal of the American Medical Association (JAMA) released a new study that disclosed the risks associated with taking Ozempic and other GLP-1 drugs. The data suggested patients taking these medications for weight loss could have an increased risk of developing digestive Ozempic side effects.

Since the release of the latest research, the number of Ozempic lawsuits has grown to the point that lawyers for many injured patients requested the formation of multidistrict litigation (MDL) to coordinate the litigation process and ensure consistent results among all related Ozempic claims. 

Increased Risk of Developing NAION and Vision Loss

A July 2024 study out of Harvard University has found a potential link between Ozempic use and a serious eye condition called nonarteritic anterior ischemic optic neuropathy, or NAION. The researchers determined that patients taking Ozempic and other drugs that contain semaglutide have a four to eight times greater chance of developing NAION. This condition can result in sudden vision loss when the optic nerve is denied oxygen flow.

Based on this preliminary research, the dangerous drug lawyers at Dolman Law Group are working with Ozempic users who have suffered vision loss to protect their rights through Ozempic vision loss lawsuits. Contact our team to learn more about this groundbreaking litigation.

Other Ozempic Side Effects Reported – Gallbladder Issues and  Gallstones

The recent Ozempic lawsuits related to gastroparesis and other digestive concerns are big news. However, they are actually the second round of personal injury claims filed due to unforeseen Ozempic side effects. Before gastrointestinal side effect cases came to light, other lawsuits claimed Ozempic use caused gallstones and other gallbladder-related problems. 

Several Ozempic patients filed suit after they were diagnosed with gallstones, medically known as cholelithiasis. In their lawsuits, these plaintiffs claim their gallstones are connected to their use of Ozempic. 

Gallstones occur when the gallbladder cannot properly process bile. Excess bile can create gallstones from the accumulated bile. Some gallstones pass through the body naturally if they are small enough. However, larger and more numerous stones can cause serious and extremely painful blockage. 

The patients bringing Ozempic gallbladder lawsuits allege the Ozempic manufacturers should have warned about this serious side effect so they could make an informed decision before taking the drug. 

Studies Reveal Ozempic Side Effects Including Gallstones 

Unfortunately, some studies have shown that one out of every six patients using Ozempic may develop gallstones. In 2017, researchers released a study after collecting data from 113 clinical trials involving GLP-1 drugs taken by patients with type 2 diabetes. The results showed an increased risk of gallstones in those patients. The same researchers conducted another study in 2020 using an updated meta-analysis to support their earlier findings. 

A Chinese study followed 76 clinical trials and found a connection between patients who used GLP-1 drugs like Ozempic and the diagnosis of gallbladder issues, including gallstones.

What Damages Can an Ozempic Lawsuit Recover?

Ozempic is a drug that many patients trust to treat diabetes and obesity. Unfortunately, many users are now suffering serious Ozempic side effects and severe health conditions, including digestive gastroparesis and gallbladder issues. 

All drugs can have negative side effects. However, under the law, drug manufacturers have a legal duty to inform and warn consumers about the risks they face when taking a drug. The pending Ozempic lawsuits allege Novo Nordisk failed to warn medical providers and patients about potential Ozempic side effects such as gallstones and stomach paralysis. 

These serious Ozempic side effects may not be life-threatening for every patient, but they may still negatively affect their finances and quality of life forever. When you file an Ozempic lawsuit, you may request compensation for both economic damages (out-of-pocket costs), such as medical expenses and lost income, as well as non-economic damages (intangible losses), including mental anguish or pain and suffering. 

Common personal injury damages an injured Ozempic user might claim in a lawsuit include:

• Medical expenses such as
  • Doctor appointments and lab tests
  • Diagnostic imaging
  • Medication to treat the Ozempic-related condition
  • Surgery to remove gallstones or relieve digestive obstructions
  • Hospital costs
• Job-related losses including
  • Lost income caused by receiving medical care or inability to work
  • Missed promotions, benefits, or loss of employment
• Pain and suffering
• Mental anguish
• Reduced quality of life

What Are the Potential Long-Term Side Effects of Ozempic?

Patients use semaglutide and other GLP-1 agonists for extended periods, possibly for their lifetime, especially if used as weight-management medications. However, according to a JAMA Medical News and Perspectives study, we still have a limited understanding of the possible long-term side effects of Ozempic, especially among patients taking GLP-1 drugs to fight obesity.

Based on rodent studies, GLP-1 drugs may cause medullary thyroid cancer. However, because cancer usually develops slowly over time, we will need many years to accumulate sufficient data to show a causal impact between Ozempic use and cancer.

Recent Ozempic side effect research is also shifting focus from digestion-related problems to potential vision problems experienced by people taking GLP-1 agonists to treat obesity. A few studies are analyzing a possible increased risk of retinopathy in patients taking semaglutide to treat type 2 diabetes.

These preliminary findings emphasize a growing need for ongoing research to reveal the long-term complications related to Ozempic use, especially regarding potential health risks. If you have questions about Ozempic side effects, talk to your doctor first. Then, consult with the experienced legal professionals at Dolman Law Group for legal guidance.

Updates to Ozempic Lawsuits – November 2025

November 1, 2025 – Ozempic Lawsuits Continue to Rise as New Health Risks Come to Light

As of October 2025, more than 2,800 Ozempic lawsuits are pending in federal court and that number keeps growing. These lawsuits claim that drug manufacturers like Novo Nordisk failed to properly warn patients and doctors about the risks associated with these medications. For many individuals, the side effects have been life-altering.

What Injuries Are at the Center of the Lawsuits?

The most commonly reported complications include the following conditions. These are also the cases we are accepting at this time:

• Gastroparesis (stomach paralysis): A condition that slows or stops the movement of food from the stomach to the small intestine, often causing severe nausea, vomiting, and chronic pain.
  
• NAION (vision loss): A rare and permanent eye condition that can cause sudden blindness in one eye. A new study recently found that people taking GLP-1 drugs were twice as likely to develop NAION compared to those on other diabetes medications.
  
• Acute Kidney Injury (AKI): An analysis of FDA data shows that hundreds of semaglutide users reported kidney damage, adding to concerns about long-term organ health.
  

These are not minor side effects—they’re serious medical issues that can dramatically affect your quality of life.

What’s Happening in the Court System?

The lawsuits against Novo Nordisk and Eli Lilly are currently part of a federal multidistrict litigation (MDL) and right now, both sides are working through expert discovery. The court recently extended disclosure and motion deadlines into 2026. 

Once that phase is complete, a group of representative “bellwether” cases will be selected for early trials. These trials help determine how juries might respond to the evidence, and they often set the stage for future settlement discussions.

Legal Pressure Builds on Novo Nordisk Directors

In a surprising development, seven members of Novo Nordisk’s board of directors recently resigned, including the company’s chair and vice chair. This shake-up comes amid growing scrutiny over the company’s handling of safety concerns and its rapid push to dominate the weight-loss drug market.

Options for People Harmed by Ozempic

At Dolman Law Group, we’re here to support individuals who have been harmed by unsafe medications. If you’ve experienced vision changes, persistent stomach issues, or kidney complications after taking Ozempic or a related drug, you may be eligible to file a claim.

We offer free consultations and can help you understand your rights so you don’t have to face this process alone.

OCTOBER 1, 2025 – A SHIFT TOWARD VISION LOSS CLAIMS

Ozempic patients who experienced sudden vision loss after taking Ozempic or a similar medication may now have a strong legal path forward.

While earlier Ozempic lawsuits focused on stomach paralysis (gastroparesis), many of those cases have proven difficult to link directly to the drug, especially in people with diabetes. But another injury is now taking center stage: NAION, a rare and often permanent type of optic nerve damage that can cause partial or total blindness.

NAION Basics

• NAION cases are gaining traction because the damage is sudden, serious, and easier to link to the medication.
  
• In 2024, European regulators required drugmakers to add vision loss warnings to Ozempic and other GLP-1 medications. This was a major step that supports injured patients’ claims, but the US did not follow suit.
  
• For many users, this type of blindness came out of nowhere, with no warning, no prior eye disease, and no idea this was even a possible risk.
  

Will There Be a New MDL for Vision Loss?

In a surprising move, drugmaker Eli Lilly has asked federal courts to consolidate all vision-related lawsuits into one national proceeding. This includes claims related to Ozempic, Wegovy, Mounjaro, and other GLP-1 drugs.

The company wants the same judge—Judge Karen Marston in Pennsylvania—to handle both gastrointestinal and vision loss cases, arguing it would streamline the process. Many legal experts see this as a tactical move, but if approved, it could accelerate progress for victims with NAION claims.

At the same time, more than 30 vision-related lawsuits are pending in New Jersey, with more expected to follow.

The Ozempic Cases We are Accepting

Dolman Law Group is currently reviewing:

• Vision loss cases, including NAION
  
• Severe stomach paralysis (gastroparesis), but only when confirmed by a gastric emptying test
  

If you’ve suffered one of these serious side effects, we encourage you to reach out. You may be entitled to significant compensation for your injuries, medical expenses, and emotional trauma.

If you’ve lost your vision after using Ozempic, Mounjaro, or another GLP-1 drug, contact Dolman Law Group today. Our attorneys are committed to helping you get the answers and the justice you deserve.

SEPTEMBER 1, 2025 – WHAT THE LATEST COURT RULINGS MEAN FOR PEOPLE INJURED BY OZEMPIC AND SIMILAR DRUGS

If you or someone you love has experienced serious side effects after taking Ozempic, Wegovy, or Mounjaro, there’s been a major development that could affect your ability to pursue a legal claim.

A federal judge overseeing thousands of lawsuits against the manufacturers of these drugs has ruled that cases involving gastroparesis (stomach paralysis) can move forward… but with one important condition. The court now requires that any plaintiff claiming gastroparesis must provide objective medical evidence, such as a gastric emptying study, to support the diagnosis.

This is a tough blow for some people who were clearly suffering, but whose doctors relied on symptoms alone to diagnose their condition. Sadly, those individuals may not be able to pursue compensation under this ruling.

But there’s good news, too.

The judge rejected the drug companies’ efforts to dismiss most of the claims in the case. Specifically, she ruled that patients can move forward with allegations that Novo Nordisk and Eli Lilly failed to warn about the risks of severe gastrointestinal damage. The court also said that misleading safety claims—especially those promoted through celebrity endorsements and medical influencers—could be grounds for liability.

This means that many of the most important claims—failure to warn, breach of warranty, and state law negligence—are still very much alive. And that’s critical for people seeking justice after being harmed by these medications.

Growing Evidence of Vision Damage Raises New Concerns

Beyond stomach problems, new research is also uncovering serious risks related to vision loss. In New Jersey, more than 30 individuals have filed lawsuits claiming that Ozempic and Wegovy caused permanent eye damage, specifically a condition called NAION (non-arteritic anterior ischemic optic neuropathy). These cases may soon be consolidated into a coordinated state court proceeding, which could help speed up the process for affected individuals.

And a new study from Sweden has added to the concern. Researchers found that people taking semaglutide were more likely to develop retinal vein occlusion, a condition that can cause sudden vision loss due to blocked blood vessels in the eye. This research adds even more pressure on drugmakers to answer for the full scope of risks tied to their medications.

The Number of Lawsuits Is Rising

As of mid-August, more than 2,190 lawsuits have been filed in the federal multidistrict litigation (MDL) over injuries caused by GLP-1 drugs. Most of these lawsuits involve gastroparesis, but as more studies come out and more people step forward, that number is expected to grow.

At Dolman Law Group, we believe that drug companies have a duty to fully investigate and disclose the risks of their medications. When they fail to do so, and people suffer life-changing consequences, we are here to help them seek justice.

If you’ve been diagnosed with gastroparesis or suffered serious vision problems after using Ozempic, Wegovy, or a similar medication, reach out to our team now. We can explain your options during a free consultation.

AUGUST 1, 2025 – NEW VISION LOSS CONCERNS ADD TO GROWING SAFETY QUESTIONS ABOUT OZEMPIC AND WEGOVY

Patients who trusted drugs like Ozempic and Wegovy for help managing diabetes or weight loss are now learning that these medications may come with devastating, long-term side effects, including permanent vision loss.

Recent research from the University of Toronto has found a potential link between semaglutide (the active ingredient in both drugs) and neovascular age-related macular degeneration (nAMD), a progressive disease that damages central vision. The study showed that patients on semaglutide were twice as likely to develop the condition compared to those not taking the drug.

Macular Degeneration is Not the First Vision-Related Risk

This new finding adds to a rising number of lawsuits filed by patients who have experienced sudden and irreversible blindness caused by a condition known as NAION (non-arteritic anterior ischemic optic neuropathy). NAION occurs when blood flow to the optic nerve is disrupted, and it often results in permanent damage. Some of the most severe cases have affected individuals with no prior eye problems at all.

At the same time, more than 20 individuals in New Jersey who developed NAION after using Ozempic or Wegovy are asking the courts to consolidate their claims into a coordinated proceeding, similar to what has already occurred in the gastroparesis litigation. One recent case involves a man from Woodbridge, NJ, who says Wegovy caused his vision loss, and that Novo Nordisk failed to warn him about the risk.

Ozempic Gastroparesis MDL Growing

While over 1,800 lawsuits are now pending in the federal GLP-1 RA MDL (MDL 3094), most of those focus on stomach-related injuries. For now, the vision loss cases are proceeding separately, but that could change if more injured patients come forward.

Meanwhile, pressure is mounting on the FDA to issue a black box warning for semaglutide drugs. Medical experts and advocates say the evidence of vision-related harm is strong enough to warrant the agency’s most serious alert.

Drug Manufacturer Trying to Shift the Blame

Novo Nordisk, the drug manufacturer, is pushing back by blaming patients’ pre-existing health conditions like diabetes or high blood pressure for the side effects reported. But for those who have lost their sight with no warning, the argument rings hollow—especially as more scientific data connects semaglutide to serious eye damage.If you or a loved one suffered vision loss or gastric conditions after using Ozempic or Wegovy, you may be entitled to compensation. The attorneys at Dolman Law Group are here to listen and help you understand your legal options.

July 1, 2025 – Vision Loss Claims Jump as More Ozempic Users Face NAION Diagnoses

If you’ve suffered sudden vision loss after taking Ozempic or Wegovy, you’re not alone, and you may have legal options. Lawsuits are now piling up across the country, with growing evidence that these popular weight loss drugs may cause serious, permanent eye damage.

The most alarming reports involve a condition called NAION (non-arteritic anterior ischemic optic neuropathy). It’s a rare but devastating type of optic nerve damage that can cause irreversible blindness. More than 20 people in New Jersey have already filed lawsuits, and they’re asking the courts to consolidate their cases into a single proceeding, similar to how previous Ozempic stomach paralysis claims were handled.

One man from Woodbridge, NJ, recently sued after losing his vision while taking Wegovy, a drug with similar ingredients to those found in Ozempic. His lawsuit says the drug’s manufacturer, Novo Nordisk, never warned patients or doctors about the risk, even though they should have known.

And the risks may not stop at NAION. A new study published in JAMA Ophthalmology suggests that semaglutide (the active ingredient in Ozempic and Wegovy) may double the risk of developing macular degeneration, another disease that destroys central vision. Researchers found that even after accounting for other health factors, people on these drugs were significantly more likely to develop vision problems.

As these findings come to light, many experts, including ophthalmologists and public health advocates, are now urging the FDA to add a black box warning to Ozempic and similar drugs. That’s the strongest type of warning the agency can issue and would signal that the risk of serious eye damage is not just theoretical… It’s real.

Novo Nordisk, for its part, is already trying to defend itself by blaming patients’ pre-existing conditions like diabetes or high blood pressure. But that strategy may not hold up in court, especially when otherwise healthy people with no prior eye issues are also going blind after taking these drugs.

At Dolman Law Group, we’re following these cases closely. If you or a loved one has experienced vision loss after using Ozempic, Wegovy, or another semaglutide medication, you may be entitled to compensation for your medical costs, pain and suffering, and lost quality of life.

Call us today for a free consultation. We’re here to fight for you.

June 1, 2025 – Vision Loss Lawsuits Filed Over Ozempic’s Alleged NAION Risk

Litigation involving Ozempic continues to grow, with several new lawsuits filed against Novo Nordisk by individuals who developed non-arteritic anterior ischemic optic neuropathy (NAION)—a serious eye condition that may lead to permanent vision loss—after using the drug.

The plaintiffs in these cases allege that Novo Nordisk did not adequately warn consumers or healthcare professionals about the potential risk of NAION. They point to evidence from clinical studies, post-market monitoring, and adverse event reports that indicates a connection between semaglutide (Ozempic’s active ingredient) and optic nerve damage. Despite these findings, Ozempic’s current labeling reportedly does not include any mention of vision loss or NAION.

The number of these vision-related lawsuits is anticipated to rise. Similar claims involving other semaglutide-based drugs—Wegovy and Rybelsus, also made by Novo Nordisk—are said to be in the early stages. All three medications belong to the GLP-1 receptor agonist class and share comparable mechanisms of action.

The legal argument centers around the lack of informed consent. Plaintiffs contend that, had they been properly warned about the vision risks, they might have declined treatment. Lawyers also highlight the company’s aggressive and sometimes off-label marketing of Ozempic for weight loss as further evidence that consumer safety may have been overlooked in favor of profit.

For attorneys already pursuing claims related to stomach paralysis or gallbladder injuries linked to Ozempic, these NAION lawsuits introduce a new and potentially more serious category of injury—one that could result in significantly larger settlements due to the profound impact of blindness and the total absence of warnings.

May 2025—Over 500 New Filings Added to Ozempic MDL in April

The Ozempic multidistrict litigation (MDL No. 3094) now encompasses 1,685 active lawsuits, marking a sharp increase from the 1,148 cases reported the previous month. This surge of over 500 filings in just 30 days ranks among the fastest growth rates observed in any current mass tort.

This rapid uptick follows intensified marketing by law firms and heightened public awareness of the alleged gastrointestinal harms linked to GLP-1 receptor agonists such as Ozempic, Wegovy, and Mounjaro.

Upcoming Court Hearing on Expert Testimony

On May 14, 2025, the federal court overseeing the Ozempic multidistrict litigation is scheduled to hold a Rule 702 evidentiary hearing, commonly referred to as a Daubert hearing. This proceeding will evaluate whether the scientific opinions offered by the plaintiffs’ general causation experts meet the standards for admissibility under federal law.

The outcome of this hearing will play a significant role in determining which injury claims, such as those involving gastroparesis, can proceed toward trial. If the court finds the expert opinions to be scientifically sound, these claims may move forward. If not, certain allegations could be excluded from the litigation. Preparations for potential bellwether trials are already underway, although initial test cases are not expected to begin until late 2026 or later.

Challenges to the Master Complaint

Both Novo Nordisk and Eli Lilly have filed motions to dismiss several causes of action included in the plaintiffs’ consolidated complaint. Their position is that, aside from allegations of failure to warn, the other claims—such as those based on product design or misrepresentation—do not meet legal requirements.

Plaintiffs responded to these motions in March, asserting that Novo Nordisk’s marketing practices misled consumers about the safety of Ozempic, particularly by promoting its use for weight loss while downplaying known health risks. The court has not yet issued a ruling, but oral arguments on these motions took place in late April 2025.

Debate Over Proof Requirements for Injury Claims

Another point of contention involves the standard of evidence required to support claims that Ozempic caused specific injuries. In March, Eli Lilly requested that the court impose stricter proof requirements for plaintiffs asserting gastroparesis, such as documented results from gastric emptying tests.

Lilly argues that many individuals reporting gastrointestinal problems may not meet clinical criteria for gastroparesis and could instead be experiencing more general symptoms. In response, plaintiffs maintain that imposing such standards early in the case is unreasonable, especially since many users did not receive detailed diagnostic testing at the time of their injuries.

The presiding judge has indicated that she intends to address these broader legal and evidentiary issues early in the MDL process, as they will influence how large segments of the litigation are handled moving forward.

Gastrointestinal & Metabolic Risks

Ozempic’s well-known side effects involve the gastrointestinal (GI) system, but recent studies shed light on the frequency and severity of these events in real-world use. In April 2025, a CDC-supported research study was published in Annals of Internal Medicine analyzing U.S. emergency department data related to semaglutide. The researchers estimated that in 2022–2023, there were approximately 24,499 emergency room (ER) visits associated with the adverse effects of semaglutide in the United States.

How Our Ozempic Lawyers Can Help You

If you or someone you know has taken Ozempic and has received a gastroparesis or cholelithiasis diagnosis, call a product liability lawyer who understands the laws surrounding dangerous drugs.

When you partner with the skilled legal team at Dolman Law Group, we’ll ensure you completely understand your legal rights and options if you pursue an Ozempic lawsuit.

Understanding your rights and the complicated legal process could mean the difference between receiving a fair settlement or a winning verdict and walking away from your claim with too little or nothing at all. 

Our experienced product liability attorneys can fight for you during every step of the claims process.

Some of the valuable services we provide include: 

• Gathering evidence to build a strong claim
• Calculating your damages and being sure to include all compensable losses
• Negotiating with the insurance companies to reach a fair settlement
• Filing a lawsuit if a settlement is not possible
• Presenting your case at trial, if necessary to protect your rights

Our savvy and tenacious law firm offers professional skills and resources many other personal injury law firms can’t offer. We understand our clients are dealing with their Ozempic-related injuries and financial losses on a daily basis. We can help by overseeing your legal case, allowing you to focus on your recovery. 

Trust the Experienced Product Liability Lawyers at Dolman Law Group to Handle Your Ozempic Lawsuit

If you face severe symptoms from gallstones, stomach paralysis, or another condition you believe taking Ozemic caused, reach out to one of our product liability lawyers as soon as possible about your case.

During your free consultation, a compassionate and knowledgeable Ozempic lawyer at Dolman Law Group can share valuable information, including whether you can bring an Ozempic lawsuit and answer all your questions about recovering compensation for your losses.

One of our skilled Ozempic lawyers can evaluate your situation and explain whether you could pursue financial compensation from the makers of Ozempic or another drug. We can also discuss the potential value of your claim damages and the legal options available to you under your unique circumstances. 
Call us at 833-552-7274 or complete this simple online form today for a free consultation. We can explain your legal rights and the possible compensation you can pursue from these negligent drug makers.